Using a consecutive series of tumor blocks, enriched for tumors with ER expression between 1 and 99%, we investigated clinicopathological characteristics and features of the TME that have previously been associated with response to ICB in breast cancer. This evidence concerns the gene ESR1 and breast cancer.